> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# China Pharma Weekly Ledger (Nov 9–15, 2026): JW placement, Chipscreen IND, Jiuzhitang Ph2b & FDA 483 FOIA archive
- URL: https://chinapharmadesk.com/china-pharma-tracker-2026-11-15/
- Published: 2026-11-15T14:15:58.000Z
- Updated: 2026-11-15T14:16:02.000Z
- Description: Structured Nov 9-15, 2026 ledger covering JW Therapeutics (02126.HK) HK$160M placement, Chipscreen (688321.SS) CS231295 IND, Jiuzhitang (000989.SZ) Ph2b, Yiling (002603.SZ) approval, and FDA 483 FOIA releases.
- Author: Lin Yi
- Tags: Desk brief, Regulation, Pipeline, Market Access, Capital

This weekly reference ledger consolidates verified Chinese biopharma regulatory, clinical, financing, and compliance disclosures from November 9–15, 2026 that carry primary identifiers (`HKEX`, `CNInfo`, `CDE`, `NCT`, `openFDA`, or `FEI` numbers) but fall below standalone feature thresholds. Major policy and clinical inflection points from the same week are covered in our standalone analyses on the [FDA Complete Response Letter for ivonescimab](https://chinapharmadesk.com/akeso-summit-ivonescimab-fda-crl/), [China’s 2026 NRDL and 28-drug commercial list overhaul](https://chinapharmadesk.com/china-2026-nrdl-commercial-list-bridge/), [EMA CHMP opinions for Hansoh and Innovent](https://chinapharmadesk.com/hansoh-aumolertinib-innovent-sintilimab-chmp/), [Windward Bio’s $225 million IPO](https://chinapharmadesk.com/windward-bio-ipo-kelun-harbour-qyuns/), and [WuXi AppTec’s Section 1260H removal](https://chinapharmadesk.com/wuxi-apptec-1260h-removal-omb-deadline/).

## 1\. Capital, clinical & regulatory filings (Nov 9–15, 2026)

| Date                | Company & Code                             | Asset / Target                                             | Primary Identifier                                                                                                                                                       | Action & Key Boundaries                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| ------------------- | ------------------------------------------ | ---------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| **Nov 15, 2026**    | **JW Therapeutics** (02126.HK)             | relmacabtagene autoleucel (Carteyva, CD19 CAR-T)           | [HKEX Nov 15 filing](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1115/2026111500081.pdf?ref=chinapharmadesk.com)                                              | Agreed to issue 61,185,465 new shares at HK$2.615/share (2.97% discount to last close) for **HK$160.0 million** gross (HK$158.8 million / approx. $20.4 million net; 12.80% enlarged capital) to two institutional investors. **Completion is expressly conditional on NMPA approval of JW’s in-house lentiviral vector** for Carteyva, linking directly to its [2026 NRDL basic-insurance entry](https://chinapharmadesk.com/china-nrdl-relma-cel-cart-payment/). |
| **Nov 14, 2026**    | **Chipscreen Biosciences** (688321.SS)     | CS231295 (selective Aurora B / multi-kinase inhibitor)     | CNInfo 2026-085; CDE CXHL2601425, CXHL2601426, CXHL2601427                                                                                                               | [CDE accepted](https://static.cninfo.com.cn/finalpage/2026-11-14/1225671847.PDF?ref=chinapharmadesk.com) (Nov 13 acceptance date) three IND filings for CS231295 combination therapy in glioblastoma. Brain-penetrant small molecule; 60-working-day implied-approval clock starts from Nov 13.                                                                                                                                                                    |
| **Nov 14, 2026**    | **Jiuzhitang** (000989.SZ)                 | hBMMSC (human bone-marrow mesenchymal stem cell injection) | CNInfo 2026-073                                                                                                                                                          | Subsidiary Beijing Meike held [Phase IIb kickoff meeting](https://static.cninfo.com.cn/finalpage/2026-11-14/1225671175.PDF?ref=chinapharmadesk.com) on Nov 13 with Guangzhou Medical University First Affiliated Hospital for randomized, double-blind, placebo-controlled trial in autoimmune pulmonary alveolar proteinosis (aPAP); follows prior IND clearance and March 2026 primary endpoint completion.                                                      |
| **Nov 14, 2026**    | **Shijiazhuang Yiling** (002603.SZ)        | Qiqin Tongbi tablets (Class 1.1 innovative TCM)            | CNInfo 2026-047; Approval Z20260007 / 2026S04151                                                                                                                         | Subsidiary Beijing Yiling received [NMPA marketing approval](https://static.cninfo.com.cn/finalpage/2026-11-14/1225670272.PDF?ref=chinapharmadesk.com) (0.44 g tablet) for use with methotrexate in active rheumatoid arthritis (wind-cold-dampness syndrome).                                                                                                                                                                                                     |
| **Nov 14, 2026**    | **CDE** (NouvSight001; GC012F)             | Cell & gene therapy (“Care Plan-Extension” pilot)          | [CNPharm / CDE Nov 14 notices](https://www.cnpharm.com/c/2026-11-14/1110505.shtml?ref=chinapharmadesk.com)                                                               | CDE posted public notices admitting NouvSight001 and BCMA/CD19 FasTCAR-T GC012F into its extended patient-centric development pilot; follows [China’s broader CGT and Order No. 828 review updates](https://chinapharmadesk.com/china-nmpa-sponsor-transfer-segmented-manufacturing/).                                                                                                                                                                             |
| **Nov 13–14, 2026** | **Jiangsu Hengrui** (600276.SS / 01276.HK) | Clinical trial approvals (multiple programs)               | CNInfo 1225670611, 1225670533, 1225672309                                                                                                                                | Disclosed consecutive NMPA clinical trial approval notices alongside its [12-product 2026 NRDL filing](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1115/2026111500045.pdf?ref=chinapharmadesk.com); follows Nov 13 approval of ANGPTL3 antibody [SHR-1918](https://chinapharmadesk.com/hengrui-shr1918-angptl3-china-approval/).                                                                                                                        |
| **Nov 13, 2026**    | **RemeGen** (09995.HK / 688331.SS)         | RC118 (CLDN18.2 ADC) + RC148 (PD-1/VEGF); RC28-E           | [NCT07935369](https://clinicaltrials.gov/study/NCT07935369?ref=chinapharmadesk.com); [NCT07936487](https://clinicaltrials.gov/study/NCT07936487?ref=chinapharmadesk.com) | Newly posted Phase II/III first-line gastric/GEJ cancer trial (RC118 + RC148) and Phase IIIb DME/wAMD trial (RC28-E); both listed as NOT\_YET\_RECRUITING in China.                                                                                                                                                                                                                                                                                                |
| **Nov 12–13, 2026** | **Shanghai Henlius** (02696.HK)            | Poherdy (HLX11, pertuzumab biosimilar)                     | openFDA BLA761450                                                                                                                                                        | Recorded FDA SUPPL AP (supplemental approval) entry in openFDA Drugs@FDA alongside [Nov 15 HKEX filing](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1115/2026111500027.pdf?ref=chinapharmadesk.com) putting serplulimab across all approved China indications into 2026 NRDL Category B.                                                                                                                                                                |
| **Nov 12, 2026**    | **Fujian NHSA**                            | 12th National VBP rollout                                  | [Fujian NHSA Nov 12 notice](http://ybj.fujian.gov.cn/zfxxgkzl/fdzdgknr/qtyzdgkzfxx/202611/t20261112%5F7248468.htm?ref=chinapharmadesk.com)                               | Published provincial execution notice for China’s 12th national volume-based procurement round, complementing [earlier Beijing and Fujian VBP calendar tracking](https://chinapharmadesk.com/china-12th-vbp-provincial-calendars/).                                                                                                                                                                                                                                |

## 2\. FDA Form 483 FOIA clarifications (check inspection dates vs. Nov 2026 chatter)

Chinese GMP compliance channels circulated several U.S. FDA Form 483 documents across November 14–15, 2026\. Primary U.S. inspection records confirm these are **historical FOIA-released inspections from 2023–2025**, and should not be conflated with 2026 on-site audits:

- **Zhejiang Tianyu Pharmaceutical (`300702.SZ`, FEI `3010972581`)**: While Tianyu noted on November 11 via Shenzhen investor Q&A that a recent 2026 FDA site inspection had concluded (outcome undisclosed), the 7-observation Form 483 circulated on Chinese channels this weekend dates to **September 11–15, 2023**, and FDA’s public FOIA index also logs an inspection ending **November 29, 2024** (subsequently closed as Voluntary Action Indicated / VAI per Tianyu’s March 2025 filing).
- **Zhejiang Guobang Pharmaceutical (`605507.SH`, FEI `3008617115`)**: 1-observation Form 483 covering water-system microbial sampling dates to an inspection ending **March 3, 2025**.
- **Anhui Poly Pharmaceutical (FEI `3020871572`)**: 1-observation Form 483 covering intermediate hold-time testing dates to **February 24–27, 2025**.
- **Hangzhou Minsheng Binjiang Pharmaceutical (Inspection `1265022`)**: 3-observation Form 483 dates to **March 7, 2025**.

## Next evidence triggers

1. **JW Therapeutics (`02126.HK`)**: NMPA supplemental-application approval for in-house lentiviral vector production and completion of the HK$160.0 million placement before the long-stop date.
2. **Zhejiang Tianyu (`300702.SZ`)**: Official Establishment Inspection Report (EIR) classification (NAI/VAI/OAI) for its newly completed November 2026 FDA inspection.
3. **RemeGen (`09995.HK`)**: Patient recruitment activation on `NCT07935369` (`RC118 + RC148`) and `NCT07936487` (`RC28-E`).